This Webcast and Call Replaces and Supplements
the Chemomab Corporate Update Originally Scheduled for April 17, 2023
TEL
AVIV, Israel, April 12,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibro-inflammatory diseases with high unmet need, today
announced the company will discuss its first quarter 2023 financial
results and provide a corporate update on Thursday, May 11, 2023, at 8:00 am Eastern Time.
This webcast and call replaces and supplements a previously
announced Corporate Update event that had been scheduled for
April 17, 2023.
During the event, Chemomab's management team will review first
quarter 2023 performance, discuss recent and upcoming developments
and conduct a live question-and-answer session.
A replay of the webcast and call will be available on Chemomab's
website for 90 days at www.chemomab.com.
Live Webcast and Conference Call at 8:00 am Eastern Time, Thursday, May 11, 2023
Click this Webcast link to access the live webcast or
replay.
The live webcast and replay can also be accessed at the News
& Events section of the Investors page on
the Chemomab website
at investors.chemomab.com/events.
Conference Call Access via Telephone
- US Investors:
+1 (877) 407-9208
- International Investors: +1 (201) 493-6784
- Conference ID code: 13735393
Please call 5-10 minutes before the scheduled start
time, enter the conference passcode and ask the operator for the
Chemomab conference call.
Or click on Call meTM starting 15 minutes before
the scheduled start time for instant telephone access without
having to wait for an operator.
About Chemomab Therapeutics
Chemomab is a clinical
stage biotechnology company discovering and developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the chemokine CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to neutralize CCL24 activity. In
preclinical and clinical studies to date, CM-101 appears
well-tolerated, with the potential to treat multiple severe and
life-threatening fibro-inflammatory diseases. Encouraging results
from a Phase 2 biomarker study in NASH patients and an investigator
study in hospitalized patients with severe lung injury were
recently reported. A Phase 2 trial in primary sclerosing
cholangitis patients is ongoing and a Phase 2 systemic sclerosis
trial is expected to begin enrolling patients around midyear 2023.
For more information on Chemomab, visit chemomab.com.
Contacts:
Investors:
|
Investors &
Media:
|
Irina Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President, Investor & Public Relations,
|
ir@chemomab.com
|
Strategic
Communications
|
|
barbara.lindheim@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-discuss-first-quarter-2023-financial-results-and-provide-a-corporate-update-301795273.html
SOURCE Chemomab Therapeutics, Ltd.